Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

 



(PharmaNewsWire.Com, June 23, 2017 ) Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

For more information about this report at http://www.reportsweb.com/insulin-like-growth-factor-1-receptor-cd221-or-igf1r-or-ec-2-7-10-1-pipeline-review-h2-2016

Report Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

Request a sample copy at http://www.reportsweb.com/inquiry&RW0001506643/sample

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Company profiles

Amgen Inc.
Antisense Therapeutics Limited
Astellas Pharma Inc.
AstraZeneca Plc
Axelar AB
Boehringer Ingelheim GmbH
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab A/S
Immunomedics, Inc.
Insmed Incorporated
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Novartis AG
PharmAbcine, Inc.
Prometheon Pharma, LLC
ProteoThera, Inc.
Silver Creek Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
TyrNovo Ltd.
XL-protein GmbH


Ask for Discount at http://www.reportsweb.com/inquiry&RW0001506643/discount


List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Pipeline by Amgen Inc., H2 2016 30
Pipeline by Antisense Therapeutics Limited, H2 2016 31
Pipeline by Astellas Pharma Inc., H2 2016 32
Pipeline by AstraZeneca Plc, H2 2016 33
Pipeline by Axelar AB, H2 2016 34
Pipeline by Boehringer Ingelheim GmbH, H2 2016 35
Pipeline by Eli Lilly and Company, H2 2016 36
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37
Pipeline by Genmab A/S, H2 2016 38
Pipeline by Immunomedics, Inc., H2 2016 39
Pipeline by Insmed Incorporated, H2 2016 40
Pipeline by Merck & Co., Inc., H2 2016 41
Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 42
Pipeline by Novartis AG, H2 2016 43
Pipeline by PharmAbcine, Inc., H2 2016 44
Pipeline by Prometheon Pharma, LLC, H2 2016 45
Pipeline by ProteoThera, Inc., H2 2016 46
Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 47
Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 48
Pipeline by TyrNovo Ltd., H2 2016 49
Pipeline by XL-protein GmbH, H2 2016 50
Dormant Projects, H2 2016 100
Dormant Projects (Contd..1), H2 2016 101
Dormant Projects (Contd..2), H2 2016 102
Dormant Projects (Contd..3), H2 2016 103
Dormant Projects (Contd..4), H2 2016 104
Dormant Projects (Contd..5), H2 2016 105
Dormant Projects (Contd..6), H2 2016 106
Discontinued Products, H2 2016 107
Discontinued Products (Contd..1), H2 2016 108
Discontinued Products (Contd..2), H2 2016 109
Discontinued Products (Contd..3), H2 2016 110


Purchase Complete Report at http://www.reportsweb.com/buy&RW0001506643/buy/3500



ReportsWeb.com

Priya Sisodia

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC